ELEKTA B SHS UNSP/ADR - EKTAY STOCK NEWS

The Board of Directors of Elekta has proposed an additional dividend of SEK 0.90 per share for the fiscal year 2019/20, totaling approximately SEK 344 million. This proposal aims to align the total dividend with the previous year's level, contributing to a total dividend of SEK 1.80 per share. The Board will call for an Extraordinary General Meeting in April 2021 to finalize the decision. This decision comes amid assessments of the general economic outlook and the impact of Covid-19.

Elekta (EKTA-B.ST) has won a significant arbitration case against Livian GmbH, as determined by the London Court of International Arbitration. The court has completely rejected all claims against Elekta group companies, concluding the dispute. This outcome was reported in Elekta's latest interim report for Q3 2020/21. The ruling strengthens Elekta's position in the market, potentially protecting its business interests and investor confidence.

Elekta announced that its proton therapy planning solution, Monaco, has obtained 510(k) clearance from the U.S. FDA. This solution enhances proton therapy with efficient optimization using the Monte Carlo algorithm, allowing for rapid treatment plan creation. Elekta's collaboration with IBA strengthens its position in proton therapy, facilitating integration in clinical settings and improving patient care. The partnership aims to enhance operational efficiency and reduce costs through advanced oncology workflows and comprehensive analytics.

Elekta has appointed Johan Adebäck as the permanent Chief Financial Officer, effective immediately. Adebäck has served as the Acting CFO since June 2, 2020, and has an extensive background in finance, including his previous role as Group Treasurer since 2004. Elekta's President and CEO, Gustaf Salford, praised Adebäck for his integrity and proficiency. Adebäck holds a Bachelor's degree in Business Administration and Economics from Stockholm University. This announcement was made on February 25, 2021, as part of Elekta's compliance with the Securities Markets Act.

Elekta announced the early adoption of its MOSAIQ 3 software series by several cancer centers. This version enhances automation and simplifies user interfaces, aimed at improving workflow efficiency and accuracy. MOSAIQ 3, which received US 510(k) clearance in December 2020, features include a 2D Image Review Workspace, protocol-driven automation, and improved oncology workflows. Celebrating its 30th year in clinical use, MOSAIQ was recognized as "Best in KLAS" in 2021, highlighting its continuous improvement and responsiveness to customer feedback.

Elekta announced the establishment of a permanent office in Cairo, Egypt, to address the regional shortage of radiotherapy systems. The company has signed an agreement to acquire the oncology division of its previous distributor, Horizon for Medical Appliances, aiming to enhance customer service. This new office will serve as a hub for N. Africa’s population of 200 million, offering improved precision radiation therapy. The office is set to open in March 2021. Elekta has a long-standing presence in Egypt, contributing to cancer treatment advancements.

Elekta has scheduled a presentation for investors and analysts to discuss its third quarter results for 2020/21 on February 25, 2021, at 10:00 a.m. CET. The interim report will be released earlier that day at 7:30 a.m. CET. President and CEO Gustaf Salford, along with acting CFO Johan Adebäck, will present the company’s performance, followed by a Q&A session. The presentation will be available via live webcast, and additional details including phone numbers for the conference call are provided. The company continues to be a key player in precision radiation medicine.

Elekta announced a partnership with the U.S. Department of Veterans Affairs to integrate its ProKnow cloud solution into the VA's radiation oncology network. This collaboration aims to enhance data accessibility across 41 VA facilities, improving treatment management for over 45,000 veterans receiving radiotherapy annually. ProKnow's capabilities will allow for real-time data analysis and standardization of care practices. Elekta's commitment to veterans is further emphasized as many of its employees are veterans themselves, making this initiative particularly meaningful.